Technical Analysis for RLMD - Relmada Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | -4.30% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -4.30% | |
| Bollinger Band Squeeze | Range Contraction | -4.30% | |
| NR7 | Range Contraction | -4.30% | |
| Narrow Range Bar | Range Contraction | -4.30% |
| Alert | Time |
|---|---|
| Down 3% | 1 day ago |
| Lower Bollinger Band Support | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 2 % | 1 day ago |
| Fell Below Lower Bollinger Band | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Disease Neuroscience Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Neurotransmitters Psychiatric And Neurological Disorders N Methyl D Aspartic Acid Nmda Receptor Antagonists
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Disease Neuroscience Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Neurotransmitters Psychiatric And Neurological Disorders N Methyl D Aspartic Acid Nmda Receptor Antagonists
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.2225 |
| 52 Week Low | 2.3601 |
| Average Volume | 144,094 |
| 200-Day Moving Average | 3.76 |
| 50-Day Moving Average | 4.41 |
| 20-Day Moving Average | 3.69 |
| 10-Day Moving Average | 3.63 |
| Average True Range | 0.28 |
| RSI (14) | 31.97 |
| ADX | 33.78 |
| +DI | 10.68 |
| -DI | 23.91 |
| Chandelier Exit (Long, 3 ATRs) | 3.89 |
| Chandelier Exit (Short, 3 ATRs) | 4.15 |
| Upper Bollinger Bands | 4.00 |
| Lower Bollinger Band | 3.37 |
| Percent B (%b) | -0.05 |
| BandWidth | 17.03 |
| MACD Line | -0.26 |
| MACD Signal Line | -0.27 |
| MACD Histogram | 0.0078 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.61 | ||||
| Resistance 3 (R3) | 3.63 | 3.57 | 3.57 | ||
| Resistance 2 (R2) | 3.57 | 3.50 | 3.56 | 3.55 | |
| Resistance 1 (R1) | 3.45 | 3.46 | 3.42 | 3.43 | 3.53 |
| Pivot Point | 3.39 | 3.39 | 3.37 | 3.38 | 3.39 |
| Support 1 (S1) | 3.27 | 3.32 | 3.24 | 3.25 | 3.15 |
| Support 2 (S2) | 3.21 | 3.28 | 3.20 | 3.13 | |
| Support 3 (S3) | 3.09 | 3.21 | 3.12 | ||
| Support 4 (S4) | 3.07 |
